Natera, Inc.

Natera, Inc.

288.48
USD
-30.61
(-9.59%)
-1.16EPS
59.66BMarket Cap
Mar 04Next Earn
Natera, Inc.
NASDAQ:NTRA
(Nasdaq Stock Market)

Recent

price

288.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
1.5
4.34
7.26
4.12
3.93
4.45
4.35
4.83
6.91
8.33
9.41
13.61
16.87
20.47
Revenue per Share
-1.01
-0.14
-2.68
-1.95
-2.58
-2.22
-1.79
-2.84
-5.21
-5.57
-3.78
-1.53
-1.52
-1.16
Basic EPS, GAAP
-0.88
0.01
-1.74
-1.88
-2.02
-1.29
-0.98
-2.49
-4.15
-4.87
-2.49
0.47
0.56
0.22
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.84
-3.83
3.67
2.02
0.47
0.52
3.57
5.64
6.87
6.34
6.4
9.01
12.26
12.95
Book Value per Share
-3.84
-3.83
3.67
2.02
0.47
0.52
3.57
5.64
6.87
6.34
6.4
8.93
8.57
9.53
Tangible Book Value per Share
37
37
26
52
53
58
70
81
91
98
115
125
137
142
Basic Weighted Avg Shares
55
159
190
213
210
258
302
391
625
820
1,083
1,697
2,306
2,909
Sales/Revenue/Turnover
-45.8
0.42
-31.43
-47.55
-64.56
-44.49
-43.22
-55.31
-74.85
-65.96
-41.22
-13.1
-13.44
-8.95
Operating Margin (%)
3
5
6
6
7
8
8
9
11
17
24
31
43
77
Depreciation Expense
-37
-5
-70
-100
-138
-128
-125
-230
-472
-548
-435
-190
-208
-165
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-67.26
-3.23
-36.92
-47.21
-65.65
-49.74
-41.29
-58.76
-75.42
-66.79
-40.16
-11.22
-9.03
-5.66
Profit Margin (%)
26
77
170
78
75
127
343
664
874
901
951
1,032
1,056
1,110
Working Capital
22
24
- -
- -
73
73
100
224
341
358
350
97
118
143
LT Debt
-172
-171
185
106
25
32
279
486
653
706
765
1,195
1,712
1,870
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-68.9
-208.7
-445.14
-80.31
-60.07
-82.79
-80.62
-59.11
-19.42
-14.32
-10.55
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
95
95
96
LT Borrowings
- -
- -
- -
LT Finance Leases
145
143
143
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
143
144
144
Market Capitalization
28,545
38,983
59,659

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,652
1,659
1,723
Cash, Cash Equivalents & STI
1,088
1,092
1,097
Accounts Receivable, Net
418
422
471
Inventories
71
80
92
Total Current Liabilities
558
553
613
Payables & Accruals
273
302
358
ST Debt
95
95
96
Deferred Revenue
37
41
37

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
89.94%
30.06%
43.25%
Free Cash Flow
26.23%
-3.55%
29.56%
Net Income, GAAP
20.84%
10.79%
9.31%
Sales/Revenue/Turnover
29.56%
43.15%
35.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
368
413
440
476
1,697
2025
502
547
592
665
2,306
2026
697
753
794
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.56
-0.3
-0.26
-0.41
-1.53
2025
-0.5
-0.74
-0.64
0.34
-1.52
2026
-0.6
-0.47
-0.42
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.

Company News

  • Natera, Inc. $NTRA Stock Sold by Eurizon Capital SGR S.p.A.

  • Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

  • Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

  • Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript

  • Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

  • Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

  • Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook

  • NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

  • Natera, Inc. $NTRA Stock Holdings Lessened by Candriam S.C.A.

  • Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock

  • Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock

  • Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock

  • Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript

  • Natera Stock Plummets After Mixed Q3 Financials

  • What Natera (NTRA) Said on Its Q3 Earnings Call

  • Allspring Growth Fund Q3 2026 Performers And Detractors

  • Alger Concentrated Equity ETF Q3 2026 Portfolio Update

  • Natera Announces Leadership Transition

  • Natera Reports Third Quarter 2026 Financial Results

  • Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers